Stephen Lautens
-
Steve Saviuk of Valeo Pharma talks about acquiring new therapeutic drugs and record Q3 revenue
In this interview, InvestorIntel Publisher and Editor in Chief Stephen Lautens talks to Valeo Pharma Inc.’s (TSX: VPH…
-
InvestorIntel Appoints Publisher & Editor In Chief Stephen Lautens As Director
InvestorIntel Corp. is pleased to announce the appointment of Stephen Lautens as its new Director. He will continue…
-
InvestorIntel Week in Review for June 13-20, 2022
Ever imagine what the world would look like if you closed your eyes and then saw the world…
-
Thomas Smeenk of Hemostemix talks about market reaction to successful litigation settlement
In this InvestorIntel interview with host Stephen Lautens, Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and…
